ATE293993T1 - Impfstofformulierung mit monoglyceriden oder fettsäuren als adjuvans - Google Patents

Impfstofformulierung mit monoglyceriden oder fettsäuren als adjuvans

Info

Publication number: ATE293993T1
Authority: AT; Austria
Prior art keywords: sub; vaccine formulation; formulation; fatty acids; sup
Prior art date: 1999-02-12

Application number

AT00903678T

Other languages

English (en)

Inventor

Ulf Schroeder

Stefan Svenson

Original Assignee

Eurocine Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-02-12

Filing date

2000-02-09

Publication date

2005-05-15

2000-02-09 Application filed by Eurocine Ab filed Critical Eurocine Ab

2005-05-15 Application granted granted Critical

2005-05-15 Publication of ATE293993T1 publication Critical patent/ATE293993T1/de

Links

239000000203 mixture Substances 0.000 title abstract 6
238000009472 formulation Methods 0.000 title abstract 5
239000002671 adjuvant Substances 0.000 title abstract 3
229960005486 vaccine Drugs 0.000 title abstract 3
235000014113 dietary fatty acids Nutrition 0.000 title abstract 2
229930195729 fatty acid Natural products 0.000 title abstract 2
239000000194 fatty acid Substances 0.000 title abstract 2
150000004665 fatty acids Chemical class 0.000 title abstract 2
OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical compound CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 title 1
LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 abstract 2
230000003053 immunization Effects 0.000 abstract 2
244000005700 microbiome Species 0.000 abstract 2
WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 abstract 1
RZRNAYUHWVFMIP-KTKRTIGZSA-N 1-oleoylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-KTKRTIGZSA-N 0.000 abstract 1
LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 abstract 1
QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 abstract 1
241000187479 Mycobacterium tuberculosis Species 0.000 abstract 1
ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 abstract 1
239000005642 Oleic acid Substances 0.000 abstract 1
125000002252 acyl group Chemical group 0.000 abstract 1
125000000837 carbohydrate group Chemical group 0.000 abstract 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
239000000969 carrier Substances 0.000 abstract 1
RZRNAYUHWVFMIP-HXUWFJFHSA-N glycerol monolinoleate Natural products CCCCCCCCC=CCCCCCCCC(=O)OC[C@H](O)CO RZRNAYUHWVFMIP-HXUWFJFHSA-N 0.000 abstract 1
230000002163 immunogen Effects 0.000 abstract 1
QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 abstract 1
229940074096 monoolein Drugs 0.000 abstract 1
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 abstract 1
238000002360 preparation method Methods 0.000 abstract 1
235000012424 soybean oil Nutrition 0.000 abstract 1
239000003549 soybean oil Substances 0.000 abstract 1
239000000126 substance Substances 0.000 abstract 1
229960000814 tetanus toxoid Drugs 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Mycology (AREA)
Microbiology (AREA)
Immunology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Communicable Diseases (AREA)
Pulmonology (AREA)
Oncology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicinal Preparation (AREA)

AT00903678T 1999-02-12 2000-02-09 Impfstofformulierung mit monoglyceriden oder fettsäuren als adjuvans ATE293993T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
SE9900496A SE9900496D0 (sv)	1999-02-12	1999-02-12	Vaccine formulation
PCT/EP2000/001038 WO2000047224A2 (en)	1999-02-12	2000-02-09	Vaccine formulation comprising monoglycerides or fatty acids as adjuvant

Publications (1)

Publication Number	Publication Date
ATE293993T1 true ATE293993T1 (de)	2005-05-15

Family

ID=20414470

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT00903678T ATE293993T1 (de)	1999-02-12	2000-02-09	Impfstofformulierung mit monoglyceriden oder fettsäuren als adjuvans

Country Status (9)

Country	Link
US (1)	US6890540B1 (de)
EP (1)	EP1150713B1 (de)
AT (1)	ATE293993T1 (de)
AU (1)	AU769375B2 (de)
DE (1)	DE60019726T2 (de)
DK (1)	DK1150713T3 (de)
NZ (1)	NZ513129A (de)
SE (1)	SE9900496D0 (de)
WO (1)	WO2000047224A2 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2352671T3 (es) *	2002-11-26	2011-02-22	Eurocine Vaccines Ab	Nuevo adyuvante a base de amina.
US7349378B2 (en) *	2003-02-24	2008-03-25	Toshiba America Research, Inc.	Local area network resource manager
US20080044440A1 (en) *	2004-02-18	2008-02-21	Margaret Dunkley	Vaccine Formulated For Administration To Mucosa Of The Lungs
WO2006079989A2 (en) *	2005-01-28	2006-08-03	North-West University	Lipid and nitrous oxide combination as adjuvant for the enhancement of the efficacy of vaccines
US20090023682A1 (en) *	2007-07-19	2009-01-22	Joseph Artiss	Composition Comprising Dietary Fat Complexer and Methods of Using Same
US8916164B2 (en) *	2007-08-29	2014-12-23	Abivax	Methods of enhancing adjuvaticity of vaccine compositions
ES2531657T3 (es) *	2008-05-01	2015-03-18	Arecor Limited	Formulación de una proteína
WO2010144794A1 (en)	2009-06-12	2010-12-16	Vaccine Technologies, Incorporated	Baculovirus-expressed fusion polypeptide vaccines with enhanced immunogenicity and uses thereof
WO2010144797A2 (en)	2009-06-12	2010-12-16	Vaccine Technologies, Incorporated	Influenza vaccines with enhanced immunogenicity and uses thereof
CN102573883A (zh)	2009-06-12	2012-07-11	疫苗技术公司	用于促进细胞-介导的免疫应答的方法和组合物
CN114010776A (zh)	2010-06-09	2022-02-08	疫苗技术股份有限公司	用于增强抗逆转录病毒治疗的hiv感染者的治疗性免疫
RU2632651C2 (ru)	2011-05-11	2017-10-06	Чилдрен'С Медикал Сентер Корпорейшн	Модифицированный биотин-связывающий белок, слитые белки на его основе и их применение
EP2742952A1 (de)	2012-12-17	2014-06-18	Eurocine Vaccines AB	Impfstoffzusammensetzung
EP4272750A3 (de)	2013-02-07	2024-01-24	Children's Medical Center, Corp.	Proteinantigene zum schutz gegen pneumokokkenkolonisation und/oder -befall

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4847080A (en) *	1984-03-07	1989-07-11	New York Blood Center, Inc.	Pre-S gene coded peptide hepatitis B immunogens, vaccines, diagnostics, and synthetic lipide vesicle carriers
WO1990014837A1 (en) *	1989-05-25	1990-12-13	Chiron Corporation	Adjuvant formulation comprising a submicron oil droplet emulsion
SE9601158D0 (sv)	1996-03-26	1996-03-26	Stefan Svenson	Method of producing immunogenic products and vaccines
SE9602280D0 (sv)	1996-06-10	1996-06-10	Pharmatrix Ab	Immunstimulerande lipidformulering
US6350456B1 (en) *	1997-03-13	2002-02-26	Corixa Corporation	Compositions and methods for the prevention and treatment of M. tuberculosis infection
KR20050086775A (ko)	2002-11-26	2005-08-30	푸로스트 인코포레이티드	트롤리 휘일용 저어널 베어링

1999
- 1999-02-12 SE SE9900496A patent/SE9900496D0/xx unknown
2000
- 2000-02-09 EP EP00903678A patent/EP1150713B1/de not_active Expired - Lifetime
- 2000-02-09 DE DE60019726T patent/DE60019726T2/de not_active Expired - Lifetime
- 2000-02-09 AU AU25473/00A patent/AU769375B2/en not_active Ceased
- 2000-02-09 WO PCT/EP2000/001038 patent/WO2000047224A2/en not_active Ceased
- 2000-02-09 AT AT00903678T patent/ATE293993T1/de active
- 2000-02-09 NZ NZ513129A patent/NZ513129A/xx not_active IP Right Cessation
- 2000-02-09 DK DK00903678T patent/DK1150713T3/da active
- 2000-02-09 US US09/926,002 patent/US6890540B1/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
DE60019726T2 (de)	2006-04-27
SE9900496D0 (sv)	1999-02-12
WO2000047224A2 (en)	2000-08-17
EP1150713A2 (de)	2001-11-07
EP1150713B1 (de)	2005-04-27
NZ513129A (en)	2003-01-31
DE60019726D1 (de)	2005-06-02
WO2000047224A3 (en)	2000-12-14
AU2547300A (en)	2000-08-29
AU769375B2 (en)	2004-01-22
US6890540B1 (en)	2005-05-10
DK1150713T3 (da)	2005-08-29

Legal Events

Date

Code

Title

Description

2006-05-15

UEP

Publication of translation of european patent specification

Ref document number: 1150713

Country of ref document: EP

Publication	Publication Date	Title
DE60019726D1 (de)	2005-06-02	Impfstofformulierung mit monoglyceriden oder fettsäuren als adjuvans
CY1110140T1 (el)	2015-01-14	Εμβολιασμος με μηνιγγοκοκκικο συζευγμα
DK0777490T3 (da)	2006-09-18	Mutant-enterotoxin, som er effektivt som et ikke-toksisk oralt adjuvans
JP2002501033A5 (de)	2006-03-23
DE3766200D1 (de)	1990-12-20	L-dopa enthaltendes arzneimittel.
JPS568320A (en)	1981-01-28	Drug for tumor immunotherapy comprising lipopolysaccharide as active constituent
SE9602280D0 (sv)	1996-06-10	Immunstimulerande lipidformulering
BR0111834A (pt)	2003-07-08	Composições adjuvante e imunogênica, e, método para eliciar uma resposta imune a um antìgeno
EP0271909A3 (de)	1989-12-06	Triglycerid enthaltende Zusammensetzung
Rios et al.	1972	Comparative effect of Mycobacterium bovis-and neuraminidase-treated tumor cells on the growth of established methylcholanthrene fibrosarcomas in syngeneic mice
DK0584126T3 (da)	1997-10-20	Lanolinderivater som penetrationsfremmende stoffer
DK1154792T3 (da)	2007-02-12	Tuberkulosevaccine-formulering, der omfatter monoglycerider eller fedtsyrer som adjuvans
FI932759A0 (fi)	1993-06-16	Anvaendningen av IL-4 foer oekning av pao vacciners immunogener verkande immunreaktioner
ATE108487T1 (de)	1994-07-15	Herstellung eines desoxyribonucleosids.
SE9601158D0 (sv)	1996-03-26	Method of producing immunogenic products and vaccines
SE0100011D0 (sv)	2001-01-03	Virus vaccine formulation
DE60139404D1 (de)	2009-09-10	Parenterale impfstoff-formulierungen und deren verwendung
WO2024173723A3 (en)	2024-10-24	Use of crassocephalum rabens extract in inducing humoral immune response
GB0014438D0 (en)	2000-08-09	Immune response stimulation
佐伯英治 et al.	1989	Effect of Corynebacterium parvum bacterin on artificial immunity against Babesia rodhaini infection in mice.
Makioka et al.	1984	Immunomodulation by Tetrahymena pyriformis
RU93043610A (ru)	1997-02-10	Фармацевтическая композиция для усиления первичной иммуно-реакции у млекопитающих, способ усиления первичной иммуно-реакции и применение интерлейкина-4 для усиления первичной иммуно-реакции у млекопитающих, набор лекарственных средств